GT200100005A - Tratamiento de la enfermedad neurodegenerativa - Google Patents
Tratamiento de la enfermedad neurodegenerativaInfo
- Publication number
- GT200100005A GT200100005A GT200100005A GT200100005A GT200100005A GT 200100005 A GT200100005 A GT 200100005A GT 200100005 A GT200100005 A GT 200100005A GT 200100005 A GT200100005 A GT 200100005A GT 200100005 A GT200100005 A GT 200100005A
- Authority
- GT
- Guatemala
- Prior art keywords
- treatment
- cdk
- neurodegenerative disease
- cdk inhibitor
- inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
LA PRESENTE INVENCION TRATA DE UN METODO DE TRATAMIENTO DE LAS ENFERMEDADES NEURODEGENERATIVAS EN EL QUE SE UTILIZA, UNA CANTIDAD EFECTIVA DE UN INHIBIDOR DE LA CDK QUE TIENE ACTIVIDAD INHIBIDORA DE LA CDK5. UN INIBIDOR DE LA CDK COMO SE ENTIENDE AQUI ES CUALQUIER COMPUESTO QUE INHIBE AL MENOS EL CINCUENTA POR CIENTO (50%) DE POR LO MENOS UNA ENZIMA CDK EN UNA CONCENTRACION (IC50) DE POR LO MENOS 5.000 NANOMOLAR (NM) CUANDO SE LO EVALUA EN UN ENSAYO DE QUINASA DEPENDIENTE DE LA CICLINA ESTANDAR. LOS INHIBIDORES DE LA CDK PREFERIDOS PARA SER USADOS EN ESTA INVENCION SE DEFINEN CON LA FORMULA I, Y LAS SALES DERIVADOS DE ELLAS, EN DONDE W, X, R, SON GRUPOS FUNCIONALES DESCRITOS EN EL EXPEDIENTE.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17840000P | 2000-01-27 | 2000-01-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
GT200100005A true GT200100005A (es) | 2002-02-05 |
Family
ID=22652409
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GT200100005A GT200100005A (es) | 2000-01-27 | 2001-01-08 | Tratamiento de la enfermedad neurodegenerativa |
Country Status (22)
Country | Link |
---|---|
US (1) | US20040224958A1 (es) |
EP (1) | EP1255755A1 (es) |
JP (1) | JP2003523358A (es) |
KR (1) | KR20020070520A (es) |
CN (1) | CN1433417A (es) |
AR (1) | AR029437A1 (es) |
AU (1) | AU1808601A (es) |
BR (1) | BR0017075A (es) |
CA (1) | CA2394525A1 (es) |
CO (1) | CO5280216A1 (es) |
CZ (1) | CZ20022521A3 (es) |
GT (1) | GT200100005A (es) |
HN (1) | HN2001000012A (es) |
HU (1) | HUP0203803A3 (es) |
IL (1) | IL150742A0 (es) |
PA (1) | PA8510801A1 (es) |
PE (1) | PE20011228A1 (es) |
PL (1) | PL357634A1 (es) |
SK (1) | SK10772002A3 (es) |
SV (1) | SV2002000287A (es) |
TN (1) | TNSN01018A1 (es) |
WO (1) | WO2001055148A1 (es) |
Families Citing this family (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7053070B2 (en) * | 2000-01-25 | 2006-05-30 | Warner-Lambert Company | Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors |
US7235551B2 (en) | 2000-03-02 | 2007-06-26 | Smithkline Beecham Corporation | 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases |
NZ524806A (en) | 2000-10-23 | 2006-03-31 | Smithkline Beecham Corp | Tri-substituted 8H-pyrido[2,3-d]pyrimidin-7-one compounds |
WO2002068419A1 (fr) * | 2001-02-26 | 2002-09-06 | Tanabe Seiyaku Co., Ltd. | Derive de pyridopyrimidine ou naphthyridine |
DE60216747T2 (de) | 2001-04-09 | 2007-10-04 | Novartis Vaccines and Diagnostics, Inc., Emeryville | Guanidinoverbindungen als melanocortin-4-rezeptor (mc4-r) agonisten |
US7105667B2 (en) | 2001-05-01 | 2006-09-12 | Bristol-Myers Squibb Co. | Fused heterocyclic compounds and use thereof |
PE20030008A1 (es) | 2001-06-19 | 2003-01-22 | Bristol Myers Squibb Co | Inhibidores duales de pde 7 y pde 4 |
JP2005500294A (ja) | 2001-06-19 | 2005-01-06 | ブリストル−マイヤーズ スクイブ カンパニー | ホスホジエステラーゼ7に対するピリミジン阻害剤 |
EP1453516A2 (de) | 2001-10-17 | 2004-09-08 | Boehringer Ingelheim Pharma GmbH & Co.KG | 5-substituierte 4-amino-2-phenylamino-pyrimdinderivate und ihre verwendung als beta-amyloid modulatoren |
JP4460292B2 (ja) | 2001-10-17 | 2010-05-12 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | ピリミジン誘導体、これらの化合物を含む医薬組成物、その使用及びその調製方法 |
KR20060111716A (ko) | 2002-01-22 | 2006-10-27 | 워너-램버트 캄파니 엘엘씨 | 2-(피리딘-2-일아미노)-피리도[2,3-d]피리미딘-7-온 |
RU2004133811A (ru) * | 2002-04-19 | 2005-04-20 | Смитклайн Бичам Корпорейшн (US) | Новые соединения |
WO2004043367A2 (en) | 2002-11-06 | 2004-05-27 | Bristol-Myers Squibb Company | Fused heterocyclic compounds and use thereof |
CA2502970A1 (en) * | 2002-11-28 | 2004-06-10 | Schering Aktiengesellschaft | Chk-, pdk- and akt-inhibitory pyrimidines, their production and use as pharmaceutical agents |
US7157455B2 (en) * | 2003-02-10 | 2007-01-02 | Hoffmann-La Roche Inc. | 4-Aminopyrimidine-5-one derivatives |
CA2523261C (en) | 2003-05-05 | 2009-07-07 | F. Hoffmann-La Roche Ag | Fused pyrimidine derivatives with crf activity |
DK1685131T3 (da) | 2003-11-13 | 2007-07-09 | Hoffmann La Roche | Hydroxyalkylsubstituerede pyrido-7-pyrimidin-7-oner |
PT1713806E (pt) * | 2004-02-14 | 2013-08-27 | Irm Llc | Compostos e composições como inibidores da proteína quinase |
CA2555724A1 (en) * | 2004-02-18 | 2005-09-09 | Warner-Lambert Company Llc | 2-(pyridin-3-ylamino)-pyrido[2,3-d]pyrimidin-7-ones |
WO2006021547A1 (de) * | 2004-08-26 | 2006-03-02 | Boehringer Ingelheim International Gmbh | Pteridinone als plk (polo like kinase) inhibitoren |
CA2590294A1 (en) * | 2004-12-13 | 2006-06-22 | Sunesis Pharmaceuticals, Inc. | Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors |
PE20061193A1 (es) * | 2005-03-25 | 2006-12-02 | Glaxo Group Ltd | DERIVADOS DE 3,4-DIHIDROPIRIMIDO[4,5-d]PIRIMIDIN-2-[1H]-0NA COMO INHIBIDORES DE QUINASA p38 |
JP2008535822A (ja) * | 2005-03-25 | 2008-09-04 | グラクソ グループ リミテッド | 新規化合物 |
UY29440A1 (es) | 2005-03-25 | 2006-10-02 | Glaxo Group Ltd | Nuevos compuestos |
WO2006104917A2 (en) * | 2005-03-25 | 2006-10-05 | Glaxo Group Limited | Process for preparing pyrido[2,3-d]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1h)-one derivatives |
US8044062B2 (en) | 2005-10-07 | 2011-10-25 | Exelixis, Inc. | Substituted pyrido[2,3-d]pyrimidin-7(8H)-one inhibitors of phospatidylinositol 3-kinase alpha |
CN102746298A (zh) | 2005-10-07 | 2012-10-24 | 埃克塞里艾克西斯公司 | PI3Kα的吡啶并嘧啶酮抑制剂 |
KR101099926B1 (ko) | 2006-09-15 | 2011-12-28 | 화이자 프로덕츠 인코포레이티드 | 피리도 (2,3-d) 피리미디논 화합물 및 이의 pi3 억제제로서의 용도 |
CN102015704A (zh) * | 2008-04-29 | 2011-04-13 | 霍夫曼-拉罗奇有限公司 | Jnk的嘧啶基吡啶酮抑制剂 |
WO2010039740A1 (en) | 2008-09-30 | 2010-04-08 | Exelixis, Inc. | PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα AND MTOR |
CN102177161A (zh) * | 2008-10-22 | 2011-09-07 | 霍夫曼-拉罗奇有限公司 | Jnk的嘧啶基吡啶酮抑制剂 |
WO2011063415A2 (en) * | 2009-11-23 | 2011-05-26 | Afraxis, Inc. | Methods for treating mild cognitive impairment |
KR101754664B1 (ko) | 2009-12-18 | 2017-07-06 | 템플 유니버시티-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 | 치환된 피리도〔2,3-d〕피리미딘-7(8h)-온스 및 이의 치료 용도 |
WO2011100319A1 (en) | 2010-02-09 | 2011-08-18 | Exelixis, Inc. | Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k and mtor in combination with autophagy inhibitors |
WO2011156640A2 (en) * | 2010-06-09 | 2011-12-15 | Afraxis, Inc. | 8-(HETEROARYLMETHYL)PYRIDO[2,3-d]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS |
WO2011156646A2 (en) * | 2010-06-09 | 2011-12-15 | Afraxis, Inc. | 6-(sulfonylaryl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders |
US20130252967A1 (en) * | 2010-06-10 | 2013-09-26 | Afraxis, Inc. | 8-(sulfonylbenzyl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders |
EP2580217A4 (en) * | 2010-06-10 | 2014-06-18 | Afraxis Holdings Inc | 6- (ETHYNYL-) PYRIDO- [2,3-D-] PYRIMIDIN-7- (8H) -ONE FOR THE TREATMENT OF DISEASES OF THE CENTRAL NERVOUS SYSTEM |
EP2580215A4 (en) * | 2010-06-10 | 2014-01-15 | Afraxis Holdings Inc | 8- (HETEROCYCYL) PYRIDO [2,3-D] PYRIMIDIN-7 (8H) -ONES FOR THE TREATMENT OF CNS DISORDERS |
CN103200822B (zh) | 2010-08-05 | 2014-12-24 | 天普大学-联邦高等教育体系 | 2-取代-8-烷基-7-氧代-7,8-二氢吡啶并[2,3-d]嘧啶-6-腈和其应用 |
WO2012088266A2 (en) | 2010-12-22 | 2012-06-28 | Incyte Corporation | Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3 |
MX360912B (es) * | 2012-03-22 | 2018-11-22 | Oscotec Inc | Compuestos de piridopirimidina sustituida y su uso como inhibidores de tirosina cinasa 3 similar a fms. |
WO2013170671A1 (zh) * | 2012-05-14 | 2013-11-21 | 华东理工大学 | 蝶啶酮衍生物及其作为egfr、blk、flt3抑制剂的应用 |
SG11201408238WA (en) | 2012-06-13 | 2015-01-29 | Incyte Corp | Substituted tricyclic compounds as fgfr inhibitors |
US9388185B2 (en) | 2012-08-10 | 2016-07-12 | Incyte Holdings Corporation | Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors |
US9266892B2 (en) | 2012-12-19 | 2016-02-23 | Incyte Holdings Corporation | Fused pyrazoles as FGFR inhibitors |
US9815847B2 (en) | 2013-03-14 | 2017-11-14 | Icahn School Of Medicine At Mount Sinai | Pyrimidine compounds as kinase inhibitors |
EA035095B1 (ru) | 2013-04-19 | 2020-04-27 | Инсайт Холдингс Корпорейшн | Бициклические гетероциклы в качестве ингибиторов fgfr |
KR20160035411A (ko) * | 2014-09-23 | 2016-03-31 | 주식회사 오스코텍 | LRRK2 (Leucine Rich Repeat Kinase 2) 키나제 억제제로서의 피리도피리미딘 유도체 화합물 |
US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
US9580423B2 (en) | 2015-02-20 | 2017-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
MA41551A (fr) | 2015-02-20 | 2017-12-26 | Incyte Corp | Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4 |
CR20170390A (es) | 2015-02-20 | 2017-10-23 | Incyte Holdings Corp | Heterociclos biciclicos como inhibidores de fgfr |
WO2017101763A1 (en) | 2015-12-13 | 2017-06-22 | Hangzhou Innogate Pharma Co., Ltd. | Heterocycles useful as anti-cancer agents |
US10449195B2 (en) | 2016-03-29 | 2019-10-22 | Shenzhen Pharmacin Co., Ltd. | Pharmaceutical formulation of palbociclib and a preparation method thereof |
CR20190062A (es) | 2016-08-15 | 2019-05-22 | Pfizer | Inhibidores de cdk2/4/6 |
JP6545747B2 (ja) * | 2017-05-09 | 2019-07-17 | 山田化学工業株式会社 | 色素化合物 |
AR111960A1 (es) | 2017-05-26 | 2019-09-04 | Incyte Corp | Formas cristalinas de un inhibidor de fgfr y procesos para su preparación |
EA036060B1 (ru) * | 2017-07-17 | 2020-09-21 | Пфайзер Инк. | Пиридопиримидиноновые ингибиторы cdk2/4/6 |
WO2019213506A1 (en) | 2018-05-04 | 2019-11-07 | Incyte Corporation | Salts of an fgfr inhibitor |
SG11202010636VA (en) | 2018-05-04 | 2020-11-27 | Incyte Corp | Solid forms of an fgfr inhibitor and processes for preparing the same |
KR20210013154A (ko) * | 2018-05-21 | 2021-02-03 | 네르비아노 메디칼 사이언시스 에스.알.엘. | 헤테로축합된 피리돈 화합물 및 idh 억제제로서의 이의 용도 |
US20210261547A1 (en) * | 2018-06-27 | 2021-08-26 | Tufts Medical Center, Inc. | Pyridopyrimidine compounds and methods of their use |
US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
WO2020205560A1 (en) | 2019-03-29 | 2020-10-08 | Incyte Corporation | Sulfonylamide compounds as cdk2 inhibitors |
JP2022533182A (ja) * | 2019-05-16 | 2022-07-21 | ユニバーシティー オブ ヒューストン システム | タンパク質キナーゼ阻害剤ならびに疾患および状態の治療のためのその使用 |
WO2021007269A1 (en) | 2019-07-09 | 2021-01-14 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
WO2021072232A1 (en) | 2019-10-11 | 2021-04-15 | Incyte Corporation | Bicyclic amines as cdk2 inhibitors |
CR20220169A (es) | 2019-10-14 | 2022-10-27 | Incyte Corp | Heterociclos bicíclicos como inhibidores de fgfr |
WO2021076728A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Bicyclic heterocycles as fgfr inhibitors |
CN114901659A (zh) | 2019-11-26 | 2022-08-12 | 施万生物制药研发Ip有限责任公司 | 作为jak抑制剂的稠合嘧啶吡啶酮化合物 |
CA3162010A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Derivatives of an fgfr inhibitor |
JP2023505258A (ja) | 2019-12-04 | 2023-02-08 | インサイト・コーポレイション | Fgfr阻害剤としての三環式複素環 |
US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
JP2023517697A (ja) * | 2020-03-13 | 2023-04-26 | プロセネスター エルエルシー | CDK阻害剤としてのピリド[2,3-d]ピリミジン-7(8H)-オン |
CN114306245A (zh) | 2020-09-29 | 2022-04-12 | 深圳市药欣生物科技有限公司 | 无定形固体分散体的药物组合物及其制备方法 |
CA3220274A1 (en) | 2021-06-09 | 2022-12-15 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5733920A (en) * | 1995-10-31 | 1998-03-31 | Mitotix, Inc. | Inhibitors of cyclin dependent kinases |
FR2741881B1 (fr) * | 1995-12-01 | 1999-07-30 | Centre Nat Rech Scient | Nouveaux derives de purine possedant notamment des prorietes anti-proliferatives et leurs applications biologiques |
US6498163B1 (en) * | 1997-02-05 | 2002-12-24 | Warner-Lambert Company | Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation |
AU749750B2 (en) * | 1997-02-05 | 2002-07-04 | Warner-Lambert Company | Pyrido {2,3-d} pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation |
-
2000
- 2000-11-30 JP JP2001561007A patent/JP2003523358A/ja active Pending
- 2000-11-30 IL IL15074200A patent/IL150742A0/xx unknown
- 2000-11-30 CN CN00818672A patent/CN1433417A/zh active Pending
- 2000-11-30 US US10/181,866 patent/US20040224958A1/en not_active Abandoned
- 2000-11-30 HU HU0203803A patent/HUP0203803A3/hu unknown
- 2000-11-30 EP EP00980883A patent/EP1255755A1/en not_active Withdrawn
- 2000-11-30 KR KR1020027009631A patent/KR20020070520A/ko not_active Application Discontinuation
- 2000-11-30 SK SK1077-2002A patent/SK10772002A3/sk not_active Application Discontinuation
- 2000-11-30 CA CA002394525A patent/CA2394525A1/en not_active Abandoned
- 2000-11-30 CZ CZ20022521A patent/CZ20022521A3/cs unknown
- 2000-11-30 BR BR0017075-5A patent/BR0017075A/pt not_active IP Right Cessation
- 2000-11-30 WO PCT/US2000/032572 patent/WO2001055148A1/en not_active Application Discontinuation
- 2000-11-30 PL PL00357634A patent/PL357634A1/xx not_active Application Discontinuation
- 2000-11-30 AU AU18086/01A patent/AU1808601A/en not_active Abandoned
-
2001
- 2001-01-08 GT GT200100005A patent/GT200100005A/es unknown
- 2001-01-22 SV SV2001000287A patent/SV2002000287A/es not_active Application Discontinuation
- 2001-01-24 HN HN2001000012A patent/HN2001000012A/es unknown
- 2001-01-24 PA PA20018510801A patent/PA8510801A1/es unknown
- 2001-01-25 CO CO01005602A patent/CO5280216A1/es not_active Application Discontinuation
- 2001-01-25 AR ARP010100308A patent/AR029437A1/es unknown
- 2001-01-25 PE PE2001000082A patent/PE20011228A1/es not_active Application Discontinuation
- 2001-01-26 TN TNTNSN01018A patent/TNSN01018A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
CO5280216A1 (es) | 2003-05-30 |
EP1255755A1 (en) | 2002-11-13 |
HUP0203803A2 (hu) | 2003-02-28 |
PL357634A1 (en) | 2004-07-26 |
HUP0203803A3 (en) | 2004-09-28 |
CA2394525A1 (en) | 2001-08-02 |
AU1808601A (en) | 2001-08-07 |
JP2003523358A (ja) | 2003-08-05 |
CZ20022521A3 (cs) | 2003-02-12 |
CN1433417A (zh) | 2003-07-30 |
PE20011228A1 (es) | 2002-01-18 |
SK10772002A3 (sk) | 2004-01-08 |
TNSN01018A1 (en) | 2005-11-10 |
IL150742A0 (en) | 2003-02-12 |
US20040224958A1 (en) | 2004-11-11 |
AR029437A1 (es) | 2003-06-25 |
KR20020070520A (ko) | 2002-09-09 |
PA8510801A1 (es) | 2002-12-11 |
HN2001000012A (es) | 2001-07-09 |
BR0017075A (pt) | 2002-11-05 |
SV2002000287A (es) | 2002-01-08 |
WO2001055148A1 (en) | 2001-08-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GT200100005A (es) | Tratamiento de la enfermedad neurodegenerativa | |
ECSP045004A (es) | Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades andrógeno dependientes | |
GT200100137A (es) | Pro-drogas de derivados de 4-fenil-piridina. | |
BRPI0418031A (pt) | inibidores de quinase fosfonato-substituìdos | |
CR9465A (es) | Compuestos mejorados farmacocineticamente | |
ECSP055696A (es) | Acetil 2-hidroxi-1, 3-diaminoalcanos | |
ECSP055640A (es) | Composiciones de pirazol útiles como inhibidores de gsk-3 | |
GT200600174A (es) | Pirrolopiridinas sustituidas, composiciones que las contienen, proceso de fabricacion y utilizacion | |
DE60332604D1 (de) | Azolylaminoazine als proteinkinasehemmer | |
NO20054970L (no) | Arylsubstituerte byrazolforbindelser anvendbare som kinaseinhibitorer | |
GT200300129A (es) | Derivados de heteroarilamida benzo condensada de tienopiridinas utiles como agentes terapeuticos,composiciones farmaceuticas que incluyen a los mismos y metodo para su uso | |
PE20030008A1 (es) | Inhibidores duales de pde 7 y pde 4 | |
CY1105014T1 (el) | Ο συνδυασμος ενος αναστολεα επαναπροσληψης σεροτονινης κι ενος 5-ht2c ανταγωνιστη, αντιστροφου αγωνιστη ή μερικου αγωνιστη | |
BR0317183A (pt) | Método de usar compostos de aminocianopiridina como inibidores de proteìna quinase-2 ativada por proteìna quinase ativada por mitógeno | |
ECSP055783A (es) | Derivados de fenilalanina como inhibidores de dipeptidilpeptidasa para el tratamiento o prevención de diabetes | |
ECSP056173A (es) | Composicion que comprende un inhibidor de pde4 y un inhibidor de pde5 | |
HUP0203160A2 (hu) | Plakk ruptura kialakulásának megakadályozása ACAT-inhibitorok alkalmazásával | |
ES2136037B1 (es) | Inhibidores de sulfamida-metaloproteasa | |
PA8552501A1 (es) | 1-alquil o 1-cicloalquil-triazolo[4,3-a]quinazolin-5-onas como inhibidoras de fosfodiesterasa | |
DE60010675D1 (de) | Caspase inhibitoren und deren verwendung | |
RS52945B (en) | PHARMACEUTICAL FORMULATIONS AND THEIR APPLICATION IN THE TREATMENT OF WOMEN SEXUAL DYSFUNCTION | |
GT200500215A (es) | Amidas sustituidas de àcido tienopirrolcarboxìlico, amidas del àcido pirrolotiazolcarboxìlico y anàlogos relacionados como inhibidores de la epsilon caseìna quinasa i | |
GT200100145A (es) | Derivados de pirrolidina. | |
NO20052153L (no) | Piperazin- og piperidinderivater for behandling av nevrologiske sykdommer. | |
GT200400041A (es) | Derivados azabiciclicos de piridiloximetilo y bencisoxazol |